K–115 hydrochloride dihydrate |
Catalog No.GC12817 |
K-115 hydrochloride dihydrate (K-115) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 887375-67-9
Sample solution is provided at 25 µL, 10mM.
Ripasudil (K-115) is a novel and potent Rho kinase inhibitor with intraocular pressure-lowering effect. Rho-kinase can be activated by the small GTP-binding protein Rho. Growing evidence has demonstrated that Rho/Rho-kinase pathway has been involved in a variety of cellular functions, such as actin cytoskeleton organization, vascular smooth muscle cell (VSMC) contraction, cell adhesion and motility, cytokinesis, and gene expressions. Dysfunctions of these may result in the pathogenesis of cardiovascular disease such as coronary artery spasm [1].
In vivo: In optic nerve crush (NC) C57BL/6 mice model, oral administration of K-115 (1 mg/kg/d) increased 34 ± 3% survival of RGCs after NC [2].
Clinical Trials: In the phase 1 clinical trials, 0.05%, 0.1%, 0.2%, 0.4%, and 0.8% concentrations of K-115 increased the intraocular pressure (IOP) of healthy male adult volunteers from -1.6 mm Hg for placebo to -3.4, -2.2, -2.6, -4.0, and -4.3 mm Hg when tested in 2 hours after instillation [3]. In the phase 2 randomized clinical study, in patients with primary open-angle glaucoma or ocular hypertension, K-115 treatment (twice daily for 8 weeks) dose-dependently lowered the IOP level [4].
References:
[1].Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine[J]. Arteriosclerosis, thrombosis, and vascular biology, 2005, 25(9): 1767-1775.
[2].Yamamoto K, Maruyama K, Himori N, et al. The Novel Rho Kinase (ROCK) Inhibitor K-115: A New Candidate Drug for Neuroprotective Treatment in GlaucomaNovel Rho Kinase Inhibitor[J]. Investigative ophthalmology & visual science, 2014, 55(11): 7126-7136.
[3].Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115[J]. JAMA ophthalmology, 2013, 131(10): 1288-1295.
[4].Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension[J]. American journal of ophthalmology, 2013, 156(4): 731-736. e2.
Average Rating: 5
(Based on Reviews and 33 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *